This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials, new report from Cancer Research Institute reveals.
Cancer Research Institute CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey receives inaugural Tara Withington Public Service Award from the Society for Immunotherapy of Cancer.
International neoantigen initiative Tumor Neoantigen Selection Alliance (TESLA) identifies parameters for cancer vaccine or cell therapy advancement
Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.
Cancer Research Institute goes virtual for its Immunotherapy Patient Summit Series, connecting patients and caregivers with leading experts in cancer immunotherapy.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
This Black History Month, meet a few Black leaders who have contributed to our understanding of the science of the immune system—and its protection against diseases, including cancer.
CRI experts share their latest insights on COVID-19 and cancer.